Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Carbone L, Marrelli D, Barbato B, Visani A, Corso G, Roviello F. Specific molecular signature redefines the role of posterior and para-aortic (D2 plus) lymphadenectomy in gastric cancer: Rethinking surgical indications. World J Clin Oncol 2026; 17(11): 126700 [DOI: 10.5306/wjco.126700]
World J Clin Oncol. Nov 24, 2026; 17(11): 126700 Published online Nov 24, 2026. doi: 10.5306/wjco.126700
Specific molecular signature redefines the role of posterior and para-aortic (D2 plus) lymphadenectomy in gastric cancer: Rethinking surgical indications
Ludovico Carbone, Daniele Marrelli, Bina Barbato, Aurora Visani, Giovanni Corso, Franco Roviello
Ludovico Carbone, Daniele Marrelli, Aurora Visani, Franco Roviello, Department of Medicine Surgery and Neuroscience, University of Siena, Siena 53100, Tuscany, Italy
Bina Barbato, Department of Medical Biotechnology, University of Siena, Siena 53100, Tuscany, Italy
Giovanni Corso, Division of Breast Surgery, European Institute of Oncology (IRCCS), Milan 20141, Lombardy, Italy
Giovanni Corso, Department of Oncology and Hemato-oncology, University fo Milan, Milan 20141, Lombardy, Italy
Author contributions: Marrelli D and Roviello F conceptualised and designed the study; Carbone L and Marrelli D conducted the literature review, did the analysis, interpretation of data and drafted the original manuscript; Visani A collected data; Barbato B, Visani A and Corso G made critical revisions and prepared the draft; Roviello F supervised; all authors approved the submitted version.
AI contribution statement: Figure 8C of this manuscript was edited using AI tools.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Corresponding author: Daniele Marrelli, MD, Doctor, Department of Medicine Surgery and Neuroscience, University of Siena, viale Mario Bracci 11, Siena 53100, Tuscany, Italy. daniele.marrelli@unisi.it
Received: August 11, 2026 Revised: August 28, 2026 Accepted: November 2, 2026 Published online: November 24, 2026 Processing time: 98 Days and 14.2 Hours
Abstract
Posterior and para-aortic (D2 plus) lymphadenectomy is still controversial in gastric cancer surgery, as potential oncologic benefit must be balanced against increased technical complexity. Extended lymph node dissection aims to remove residual regional disease, improve staging, and control locoregional recurrence. This review synthesizes the recent literature on D2 plus in advanced gastric cancer, with particular attention to molecular profiling, response to neoadjuvant therapy, and the role of conversion surgery in oligometastatic disease. D2 plus should not be considered routine but may be evaluated in selected patients with bulky nodes in extragastric regions or isolated para-aortic involvement responding to systemic therapy. Pathological response appears to be the strongest prognostic determinant, and persistent nodal burden after neoadjuvant chemotherapy identifies patients with poor survival. Furthermore, molecular subtypes influence biology and expected benefit from therapy: Microsatellite instable tumors may preserve limited propensity for extensive nodal spread, programmed cell death ligand 1 + expression is associated with sensitivity to immunotherapy, microsatellite stability/epithelial-mesenchymal transition is associated with aggressive behaviour and peritoneal dissemination and may benefit from prophylactic intraperitoneal chemotherapy, while human epidermal growth factor receptor 2+ tumors maintain a more uncertain behaviour. In selected patients with oligometastatic disease, D2 plus may be integrated into a conversion surgery strategy. D2 plus should be adapted to treatment response and biological profiling. Given that residual nodal burden may outweigh primary tumor response, a better understanding of the molecular features of gastric cancer may help identify patients who are most likely to benefit from posterior and para-aortic lymphadenectomy.
Core Tip: D2 plus lymphadenectomy in gastric cancer should be tailored to tumor biology and treatment response. Pathological response to neoadjuvant therapy is the strongest prognostic factor, whereas the emerging molecular characterization (microsatellite instable, programmed cell death ligand 1, epithelial-mesenchymal transition, or human epidermal growth factor receptor 2 status) predicts nodal spread pattern and tumors which likely benefit from extended nodal dissection. In selected oligometastatic patients, para-aortic lymphadenectomy can be integrated into a conversion surgery strategy to achieve complete radicality. Molecular profiling, therefore, represents a promising tool to refine treatment course and surgical indications for lymphadenectomy beyond tumor node metastasis staging alone.